VEPPANU (Vepdegestrant) Patent Expiration, LOE Window & CMS Spending

VEPPANU (Vepdegestrant) by Rigel Pharmaceuticals: FDA Orange Book core substance LOE 2038-01-30, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $29,400 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRigel Pharmaceuticals
FDA Application & PathwayN219835 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-01-30
Last Listed Patent or Exclusivity Date2038-01-30
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($29,400 intro WAC)